sorafenib,camrelizumab,rivoceranib
jiangsu hengrui pharmaceuticals,elevar therapeutics,bayer
['hcc', 'sorafenib', 'rivoceranib', 'camrelizumab', 'elevar']
check out the data presented at #esmo22. our phase 3 study compares rivoceranib in combination with camrelizumab vs sorafenib as a first-line therapy for unresectable hepatocellular carcinoma (uhcc). learn more here: 
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients.